Lingkang Pharmaceutical announced that its revenue for the first half of 2026 was 257 million yuan, an increase of 50.03% over the previous year. Net profit attributable to shareholders of listed companies was RMB 21.12,700, and net profit for the same period last year was RMB 357.3337 million, turning a loss into a profit. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $18.420,800. The company does not distribute profits or transfer capital from capital reserves to increase share capital for half a year.

Lingkang Pharmaceutical announced that its revenue for the first half of 2026 was 257 million yuan, an increase of 50.03% over the previous year. Net profit attributable to shareholders of listed companies was RMB 21.12,700, and net profit for the same period last year was RMB 357.3337 million, turning a loss into a profit. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $18.420,800. The company does not distribute profits or transfer capital from capital reserves to increase share capital for half a year.